Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.

Shanshan Hu Chenyang Shi Yuhang MaShuowen WangShengying GuChendong QiGuorong Fan

Published in: Diabetes, obesity & metabolism (2024)

This study shows that, using SEMA as a reference, the annual costs for TIRZ 10 and 15 mg are $1573.00-$1967.16 and $1576.54-$2133.96, respectively, for patients with type 2 diabetes in China.

Keyphrases

type diabetes
cardiovascular disease
glycemic control
insulin resistance
metabolic syndrome
drug induced
weight loss
adverse drug